Thematic Exposure -- 9/10
Intuitive sits at the center of three powerful secular themes reinforced by a generational
platform transition. With ~80% global market share, 11,106 installed da Vinci systems, 50,000+
trained surgeons, and 20M+ cumulative procedures, ISRG has built a near-monopoly reinforced by
the deepest surgical dataset in the world. The da Vinci 5 launch introduces Force Feedback,
10,000x computing power, and AI-powered analytics. OUS procedures grew 23% in FY2025 and now
represent ~35% of global volume. Addressable procedures have expanded to 9 million and are
growing, driven by clinical validation in benign procedures, demographics, and new clearances.
Weight: 25%
1. Robotic Surgery Monopoly / Razor-Blade Moat
~80% Global Market Share -- Dominant Installed Base
With ~80% global market share and 11,106 da Vinci systems installed at year-end FY2025, ISRG
has built a near-monopoly reinforced by: (a) 50,000+ trained surgeons with deep muscle memory,
(b) deep hospital workflow integration across scheduling, credentialing, and OR setup,
(c) over 20 million cumulative procedures generating the largest surgical dataset in the world,
and (d) a consumables-driven model where 81% of revenue recurs. Each installed system generates
~$200K+/year in instruments, accessories, and service revenue. Procedure growth -- the single
most important KPI -- was 18% globally for da Vinci in FY2025.
Global Market Share
~80%
Robotic-assisted surgery
Installed Base
11,106
Da Vinci systems, YE FY2025
Trained Surgeons
50,000+
Deep muscle memory lock-in
Cumulative Procedures
20M+
Largest surgical dataset
2. Da Vinci 5 -- Generational Platform Transition
Most Significant Platform Upgrade in a Decade
Da Vinci 5 is the most significant platform upgrade in a decade. FY2025 saw 870 dV5 placements
(of 1,721 total), with the installed base reaching 1,232 systems used by 10,000+ surgeons.
Force Feedback is the headline feature -- early studies show a 55% reduction in maximum tissue
force during suturing and faster bowel function recovery (83% vs 25% within 24 hours in a
nephrectomy study). The system delivers 10,000x computing power vs. Xi, enabling Case Insights,
AI-powered surgical analytics, and real-time 3D model overlay. DV5 already outpaces Xi
utilization, validating efficiency design intent. The MIA+ digital subscription (simulation,
Telepresence, Case Insights) creates an entirely new recurring revenue stream with renewals
beginning mid-2026. The trade-in cycle generates refurbished Xi (XiR) inventory for ASC and
international expansion.
Force Feedback
-55% Force
Max tissue force in suturing
Computing Power
10,000x
vs. Xi platform
DV5 Placements FY2025
870
Of 1,721 total placements
MIA+ Digital Sub
Mid-2026
Renewals begin, new recurring rev
3. International Expansion and Procedure Penetration
OUS 23% Growth, 35% of Global Volume
OUS procedures grew 23% in FY2025 and now represent ~35% of global volume, up from ~30%
a few years ago. General surgery remains barely penetrated globally -- benign GS procedures
grew 27% OUS in Q4 (cholecystectomy, hernia). India and distribution markets are growing
at 27%+ with greenfield account expansion. Japan awaits new reimbursement codes in June 2026
for additional robotic procedures. Ion lung biopsy is approaching halfway penetration of US
bronchoscopic biopsy, with early launches in Europe, Korea, China, and Australia. Cardiac
surgery performed 17,000 procedures in FY2025 against a TAM of ~160,000 in cleared
geographies, with FDA clearance recently received for dV5 cardiac procedures in the US.
ISRG is going direct in Italy, Spain, and Portugal via the EUR 290M ab medica acquisition,
covering a combined population of 118M.
OUS Procedure Growth
+23%
FY2025, ~35% of global volume
India / Distribution
+27%
Greenfield account expansion
Japan Reimbursement
Jun 2026
New robotic procedure codes
Ion Global Launches
995 Systems
EU, Korea, China, Australia
4. ASC / Site of Care Expansion
XiR Systems at Lower Price Points for ASCs
Management has articulated a multi-year ASC strategy using refurbished Xi (XiR) systems at
lower price points. Approximately 70% of the ASC opportunity is within existing IDN customers
where surgeons are already trained on da Vinci -- dramatically reducing adoption friction.
This expands the addressable market into lower-acuity, higher-volume procedures. ISRG placed
42 XiR systems in FY2025 and sees this as a sizable long-term opportunity. The dV5 trade-in
cycle creates a growing supply of refurbished Xi units, turning a platform transition into a
channel expansion strategy.
ASC Within Existing IDNs
~70%
Surgeons already trained
XiR Placements FY2025
42
Early innings, growing supply
Strategy
Lower Acuity
High-volume procedures in ASCs
Addressable Procedures: 9 Million and Growing
| Year | Addressable Procedures | Key Expansion Drivers |
|---|---|---|
| 2024 | ~7 million | Baseline procedures in cleared geographies |
| 2025 | ~8 million | Benign GS validation, Ion expansion |
| 2026+ | ~9 million | Cardiac clearances, nipple-sparing mastectomy, Japan reimbursement, demographics |
Addressable procedure estimates from company filings and earnings transcripts.
Key Platform Metrics (FY2025)
| Metric | FY2025 | YoY Change |
|---|---|---|
| Da Vinci Installed Base | 11,106 | +12.2% |
| Da Vinci Placements | 1,721 | +12.8% |
| Da Vinci Procedure Growth | +18% | Accelerating |
| Ion Installed Base | 995 | +23.6% |
| Ion Quarterly Procedures | 40,200 | +43.6% YoY (Q4) |
| Recurring Revenue Mix | ~81% | Stable |
| System ASP | ~$1.60M | Rising with dV5 mix |
Data sourced from Daloopa.
Score Rationale
9/10 — Exceptional thematic
positioning across multiple reinforcing secular growth vectors. ISRG holds a near-monopoly
in robotic-assisted surgery with ~80% market share, protected by 50,000+ trained surgeons,
deep hospital integration, and the largest surgical dataset in the world (20M+ procedures).
The da Vinci 5 platform is a generational upgrade delivering Force Feedback, 10,000x computing
power, AI analytics, and a new digital subscription revenue stream (MIA+). International
expansion is accelerating at 23% growth with significant runway in India (27%+), Japan
(June 2026 reimbursement), and Ion global launches. The ASC/XiR strategy opens a new channel
with ~70% of the opportunity within existing IDNs. Addressable procedures have expanded from
7M to 9M in two years through clinical validation and new clearances. The score does not reach
10 because China competitive dynamics are intensifying with local competitors gaining share in
provincial tenders, and the dV5 transition creates near-term gross margin pressure from
higher-cost systems and trade-in credits.
Data sourced from Daloopa, earnings transcripts, and company filings.